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Abstract 
 
Background and aims 
Since 2012 four US states have legalized the retail sale of cannabis for recreational use by 
adults and more are likely to follow. This report aimed to (1) briefly describe the regulatory 
regimes so far implemented; (2) outline their plausible effects on cannabis use and cannabis-
related harm; and (3) suggest what research is needed to evaluate the public health impact of 
these policy changes.  
Method 
We reviewed the drug policy literature to identify: (1) plausible effects of legalizing adult 
recreational use on cannabis price and availability; (2) factors that may increase or limit these 
effects; (3) pointers from studies of the effects of legalizing medical cannabis use; and (4) 
indicators of cannabis use and cannabis-related harm that can be monitored to assess the 
effects of these policy changes.  
Results 
Legalization of recreational use will probably increase use in the long run but the magnitude 
and timing of any increase is uncertain. It will be critical to monitor: cannabis use in 
household and high school surveys; cannabis sales; the number of cannabis plants legally 
produced; and the THC content of cannabis. Indicators of cannabis-related harms that should 
be monitored include: car crash fatalities and injuries; emergency department presentations; 
presentations to addiction treatment services; and the prevalence of regular cannabis use 
among young people in mental health services and the criminal justice system.  
Conclusions 
Plausible effects of legalizing recreational cannabis use in the USA include substantially 
reducing the price of cannabis and increasing heavy use and some types of cannabis-related 
harm among existing users. In the longer term it may also increase the number of new users. 
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Introduction  
 
Since 2012 four US states (Alaska, Colorado, Oregon and Washington State) have legislated 
to allow the sale of cannabis for recreational use by adults over the age of 21 and Washington 
State legalized growing cannabis for personal use and gifting to friends [1,2]. More states will 
vote on similar proposals in 2016 and Vermont is considering legalization [3].  
 
In this paper we discuss the probable effects of legalization on cannabis prices, social 
acceptability of cannabis use and availability and, in turn, their likely effects on cannabis use 
among current users and nonusers. We adopt a public health approach in which we assume 
that the population level adverse health effects of cannabis (see box 1 for a summary of these) 
will be related to: the number of users, the quantity and potency of the cannabis that they use, 
the frequency of their use, the contexts in which they use (e.g. when driving), and the ways in 
which cannabis legalization affects the use of alcohol, tobacco and the opioids.  
 
We first briefly describe the regulatory regimes in Colorado and Washington State and then 
outline some mechanisms by which this form of legalization may increase cannabis use. We 
then outline ways in which the cannabis market, cannabis use and cannabis-related harm can 
be monitored in „early adopter‟ states to evaluate the effects of legalization policies on 
cannabis use and cannabis-related harm. These results may inform the design of regulations 
in other US and nation states that follow the examples of Colorado and Washington. We do 
not attempt to undertake any analyses in this paper because there is insufficient data for the 
task. Our aim is to outline the analyses that will need to be done when sufficient data have 
accumulated to permit evaluations of the public health effects of these policies.  
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Legalization as implemented in Colorado and Washington 
 
Colorado and Washington commenced legal sales in January and July 2014 respectively [4-
6]. Oregon allowed sales for recreational use from medical marijuana dispensaries starting in 
October 2015 [7,8]; Alaska lawmakers published policy guidelines in November 2015, began 
accepting licence applications in February 2016, and expect to begin issuing cultivating and 
testing licences in June and retail and product manufacturing licences in September 2016 
[9,10]. (See table 1 for summary of provisions).  
 
In Colorado and Washington adults over the age of 21 can purchase up to 28.5 g from a single 
retailer [6,11,12]. Regulations differ in who is licensed to supply cannabis; in both states 
cannabis products are taxed on their sale price (at different rates) but at levels that will reduce 
legal prices to well below black market prices [4,11,12]. Drug-impaired driving is prohibited 
in both states [13].  
 
Colorado and Washington have implemented regulatory systems similar to those used to 
regulate alcohol [14], namely, state licensing of commercial entities that retail cannabis for 
profit [11]. Commercialization of sales and more efficient cannabis production and 
distribution are the likely long term outcomes of a for profit industry in the US economic and 
political system. Under the US Constitution those who sell legal commodities have 
commercial freedom of speech to advertise and promote the use of their products [15]. The 
same may not be true in other countries that choose to legalize cannabis (e.g. Canada) where 
governments may be able to regulate cannabis sales in ways that minimize adverse effects on 
public health [16,17].  
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How may legalization of recreational use increase cannabis use?  
 
The major mechanism through which legalization is likely to increase recreational cannabis 
use is by substantially reducing the price of cannabis. The reasons for the reduction in price 
are explained in more detail below. Legalization will have other effects that may increase use, 
namely, it will be easier and safer to obtain a regular supply of a commodity which it is 
lawful to purchase and consume. Users will no longer‟ have to obtain cannabis from the black 
market or grow it themselves. Criminal penalties will no longer be a deterrent to cannabis use 
which will also be more socially acceptable. These social costs of cannabis use will decline 
along with its price [18] but price is the variable whose effects on alcohol and tobacco have 
been the most thoroughly studied so we focus on the effects of legalization on price.  
 
Probable Effects of Legalization on Cannabis Price  
 
There are several reasons why the price of cannabis in a legal market will fall well below 
black market prices [18,19]. First, the price of legal cannabis need not include a black market 
premium to cover the risks of arrest or drug market violence.  
 
Second, legal production will be more efficient because it will no longer be clandestine and 
so growers will be able to increase the scale of production to reduce unit prices and pass these 
savings on to consumers. In jurisdictions where regulators allow licensees to be involved in 
production, processing, wholesale and retail sales, as they now are in Colorado, the efficiency 
of production is likely to be maximized and costs reduced more rapidly than in settings where 
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regulatory systems result in larger numbers of small scale enterprises at each step in the 
process from growing to sale [19].  
 
Third, the proposed tax regimes based on sales price will fail to keep cannabis prices at black 
market prices [19]. They may indeed provide incentives to increase the THC content of 
cannabis because this will enable producers and sellers to effectively reduce the tax rate and 
increase their profits [15]. A tax based on THC content has been recommended as one way to 
remove this incentive [3] but this suggestion has not so far been adopted by any state that has 
legalized cannabis.  
 
Data from commercial companies that aggregate consumer reports of cannabis prices show 
that cannabis prices in states that have legalized medical or recreational use are 10% below 
the national average and up to 20% lower than the prices paid in states that have not legalized 
medical or recreational use [20]. It is uncertain how much further these prices will fall and 
how soon because the number of retail outlets may be limited. Initially, state governments 
have restricted the numbers of licenced producers and retailers to make regulation easier. This 
effectively grants licensees an oligopoly on cannabis sales that reduces their need to compete 
on price. Some states also allow local governments to ban retail outlets in their jurisdictions, 
thereby restricting retail outlets to larger cities [16], as had occurred in Colorado. The fear 
that the Federal government will enforce federal laws against drug trafficking may also 
provide a brake on the large scale outdoor commercial cultivation of cannabis that would 
most rapidly reduce prices [3].  
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Plausible Effects of Legalization on Cannabis Use 
 
The use of alcohol and tobacco generally increases as their price falls and use generally 
decreases when their price increases [21-23]. There is more limited evidence that the same is 
true of the relationship between cannabis use and cannabis price [24]. This suggests that 
legalizing recreational cannabis sales will also increase cannabis use by reducing price. It is 
uncertain by how much [25] because we cannot predict either how low cannabis prices will 
go, or how much users may increase their consumption in response to large reductions in 
price [18,19].  
 
If the effects of lower prices on alcohol consumption [26] apply to cannabis use then lower 
cannabis prices are most likely to increase frequency of use among current users [18] whop 
will be able to buy more of their drug of choice for the same price. In surveys of US high 
school students, only 18% of current users say they will use more cannabis if it is (or 
becomes) legal [27] but we do not know how accurately these users can predict the effects of 
lower cannabis prices on their own use.  
 
It is less certain whether, and if so, how much, a decline in cannabis prices may increase the 
number of new cannabis users. The Monitoring the Future Surveys of US high school seniors 
report that only 10% of those who have not used cannabis say that they will do so if it is legal 
[27] but again we do not know how accurately non-users can predict their future use in a 
legal market where cannabis use is common among their peers.  
 
We can get some pointers to possible effects of cannabis legalization on cannabis use from 
studies of the effects of medical marijuana laws (MML) in some US states on cannabis use. 
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These studies have a major limitation, namely, that the liberality of medical marijuana 
regulations varies widely between states. This means that simple comparisons of rates of 
cannabis use in states that have and have not legalized medical marijuana will under-estimate 
the effects of more liberal MMLs and overestimate the impact of more tightly regulated 
MMLs [28].  
The Effects of Medical Marijuana Laws  
 
Effects on Adolescent Cannabis Use 
 
A reasonable concern is that medical cannabis laws will increase adolescent cannabis use by 
making the drug more available and sending the message that cannabis use is not risky [29]. 
Researchers have evaluated these concerns by comparing trends in cannabis use in surveys of 
adolescents in states that have and have not legalized medical cannabis use [30]. These 
surveys were not primarily designed for this evaluation task. They were designed to provide 
samples that were representative of the US high school population generally rather than of the 
high school populations of individual states. Comparisons have had to be made between the 
populations of groups of states that have legalized and not legalized medical marijuana, often 
by averaging data over two survey years to produce stable estimates. These analyses do not 
take into account large differences between the states regarding the conditions under which 
medical use of cannabis is allowed [28].  
 
Comparisons of adolescent cannabis use in household and school-based surveys have 
generally not found differences between states with and without MMLs (e.g. [31-38]). The 
largest study [39] of trends in adolescent cannabis use in Monitoring the Future Surveys 
between 1991 and 2014 compared trends in past 30 day cannabis use in the 21 states that had 
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legalized MM use with those in the 27 mainland US states which had not. The analysis 
controlled for social, economic and demographic differences between these states and 
schools. States which passed MMLs had higher rates of 30 day cannabis use before these 
laws were passed (15.9% vs 13.3%) than states that had not, indicating that states with higher 
rates of cannabis use were more likely to allow medical use. There was no increase, however, 
in adolescent cannabis use after the passage of MMLs (16.3% pre to 15.5% post).  
 
Similar results emerged from comparisons of trends in cannabis use among young people 
aged 12 to 20 in states with and without MMLs in the US National Household Survey of 
Drug Use [40]. The proportion of young people who reported using cannabis in the year after 
MMLs were passed marginally increased between 2004 and 2012 but there was no increase 
in cannabis use in the past 30 days, or in daily use, among these young people.  
 
Effects on Adult Cannabis Use 
 
Household survey data suggests that cannabis use may have increased among cannabis users 
over the age of 21 years after the passage of MMLs between 2004 and 2012 [40]. There were 
no differences in rates of initiation of cannabis use among adults between MML and non 
MML states. Adults in MML states, however, reported:  higher rates of cannabis use in the 
past 30 days (an increase of 1.32%); higher rates of daily cannabis use (an increase of 
0.58%); and higher rates of cannabis abuse/dependence (an increase of 10%) than adults in 
states that did not have MMLS.  Surveys also indicate that the prevalence of cannabis 
dependence increased in the US population between 1991-1992 and 2001-2002 [41] and 
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again between 2001-2002 and 2012-2013 [39]. No breakdown has been provided, however, 
on whether these increases were greater in states that did and did not have MMLs. 
 
One study has examined the possible effects of MMLs on treatment seeking for cannabis use 
disorders. Chu [42] compared the number of persons seeking first time treatment for cannabis 
problems between 1992 and 2011 in states with and without MMLs. After MMLs were 
passed, there was a 15-21% increase in new treatment episodes for primary cannabis use 
problems in persons who had not been referred by the criminal justice system.  
Effects on Cannabis Related Harm 
 
Evaluations of the effects of MMLs on cannabis-related motor vehicle fatalities have been 
mixed. Some studies [43] have found an increase in the percentage of cannabis-impaired 
drivers in fatal crashes in states with MMLs but interpretation is complicated by the fact that 
testing for cannabis use was less common before MMLs were enacted and more common 
thereafter.  
 
Anderson et al [44] examined the role of alcohol in car crashes between 1990 and 2010 in US 
states that did and did not have MMLs. They found an 8-11 per cent greater decrease in total 
traffic fatalities and in fatalities with a BAC > 0.08% in states with MMLs. They argued 
(using data on self-reported alcohol use and beer sales) that this effect was explained by 
young males substituting cannabis for alcohol because cannabis was cheaper in MML states.  
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A comparison of trends in fatal motor vehicle crashes in Colorado and 34 states without 
MMLs between 1994 and 2011 produced results that were inconsistent with those of 
Anderson et al [45]. These authors found a larger increase in cannabis positive fatalities in 
Colorado after 2009 than in the 34 states without MMLs. They also found no change in 
alcohol-related motor vehicle fatalities in Colorado or the 34 states without MMLs. The 
analyses of longer time series on traffic fatalities in more US states will be required to clarify 
these conflicting findings. 
 
Effects on Other Types of Drug-related Harm  
 
A number of studies have examined trends in alcohol-related harm to see if cannabis is a 
substitute for alcohol among young men in states with MMLs [46]. Wen et al‟s analysis of 
National Household Survey data on alcohol use in states with MMLs [40] found more binge 
drinking, and more concurrent use of alcohol and cannabis, among adults over 21 years in 
states with MMLs. 
 
Anderson et al reported steeper declines in suicides among males aged 20 to 30 in US states 
that legalized MM than in those that had not [47]. This finding was not supported by another 
analysis that controlled for differences between states [48] or the failure to find an association 
between suicide rates and the number of MM patients in US states between 2004 and 2010. 
[49] 
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Lower rates of opioid overdose deaths have been reported in states with MMLs than those 
without such laws and the difference in OD death rates increased over time [50]. This finding 
has been interpreted as evidence that the use of cannabis for pain relief reduces the number of 
fatal opioid overdoses. However, a correlation between time series data on opioid overdose 
deaths and state MMLs is weak evidence for a causal relationship [51]. Better evidence is 
needed, e.g. individual level data showing that cannabis and opioid use have changed in the 
ways required for a causal relationship, and that the association at state level is not explained 
by other differences between states that have and have not passed MMLs [52]. 
 
Evaluating the Effects of Legalizing Recreational Cannabis Use  
 
Effects on Cannabis Use among Youth 
 
Any increase in cannabis use among youth after legalization will probably be preceded by 
reductions in the perceived risks, and increases in the social acceptability, of using cannabis. 
This pattern was observed with increased cannabis use in the Monitoring the Future Surveys 
in the USA in the 1970s and the converse was observed during the 1980s, when increased 
perceptions of risk and declining social acceptability were followed by a decline in cannabis 
use [53,54]. The Monitoring the Future data will provide a useful baseline against which to 
evaluate any effects of legalization on these attitudes.  
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Another leading indicator of future increases in youth cannabis use will be an increased 
frequency of use among youth who already use cannabis, or are at higher risk of doing so. 
This could be detected in surveys of youth in high schools who are counselled for conduct or 
school problems, youth in the juvenile justice system, and youth seeking treatment for 
anxiety, depression and psychosis.  
 
Effects on Cannabis Use in Adults  
 
A number of cannabis-related harms may be expected to increase if adults who already use 
cannabis do so more frequently. These include: convictions for cannabis-impaired driving; 
car crash fatalities and injuries involving cannabis-intoxicated drivers; and emergency 
department (ED) attendances for the adverse effects of ingesting cannabis products with 
higher than usual THC content.  
 
We may or may not expect to see more adults seeking professional help for problems related 
to their cannabis use, for reasons outlined below. An earlier indication of increased cannabis 
problems in adults may be provided by survey data in which non-users are asked whether 
they have expressed concerns to a family member, or a friend about their cannabis use. 
Cannabis users can also be asked whether a family member has expressed concern about their 
cannabis use. Similar questions have been used to track population trends in problem alcohol 
use [55]. 
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If the ADAM system of monitoring drugs used by arrestees [56] had not been discontinued, 
researchers could have used these data to monitor trends in the amount of THC consumed by 
groups of heavy cannabis users. In its absence, the next best option may be to monitor THC 
levels in the Fatality Analysis Reporting System [57,58].  
 
Population levels of cannabis use may potentially be assessed via the analysis of cannabis 
metabolites in waste water. Regular sampling and analysis of cannabinoid metabolites in 
waste water may be able to establish whether the total amount of cannabis used in the 
population is stable or increasing, without telling us about the number of users [59]. This will 
require the solution of analytical challenges in estimating THC and its metabolites in waste 
water.  
Possible Effects of Legalization on Indicators of Cannabis-related Harm 
 
Acute Adverse Effects 
 
Greater access to cheaper and more potent cannabis is likely to increase presentations to 
emergency departments (ED). Monte et al [60] have reported increases in cannabis-related 
ED presentations in Boulder, Colorado after the legalization of cannabis. These included 
increased numbers (from a low base rate) of: childhood poisonings from the accidental 
ingestion of edible cannabis products packaged like confectionary; cannabis intoxication in 
adults marked by unpleasant psychological reactions; a severe vomiting syndrome in heavy 
users of very potent cannabis products; and severe burns among users who attempted to 
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extract THC from cannabis oils using butane. With the exception of the burns, these adverse 
effects occurred in users of edible cannabis products.  
 
Studies of cannabis-related ED presentations should also assess the prevalence of rarer, more 
serious cardiovascular outcomes, such as, myocardial infarctions, acute coronary syndromes 
and strokes in young adults. Case series and case-control studies have reported these 
outcomes in young adults smoking potent forms of cannabis in France [61-64] and in a 
number of EU states [65].  
 
Effects on Treatment Seeking 
 
As noted above, there are indications of increased rates of cannabis dependence symptoms in 
epidemiological surveys and more adults are voluntarily seeking treatment since the 
legalization of medical cannabis use. It is less certain how the legalization of recreational 
cannabis use may affect treatment seeking. Treatment seeking could be delayed, for example, 
if the fact that cannabis is legal and cheap reduces social pressure from families and friends to 
seek treatment. Any increase in the number of problem cannabis users who seek treatment 
voluntarily could be offset by a decline in the number of adult cannabis users who are legally 
coerced into treatment, as has happened in Colorado [66]. Adolescents with cannabis use 
problems will still be coerced into treatment, and these numbers may well increase, if courts 
refer more adolescents to treatment. 
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Useful information on these issues can be collected from US national treatment data [67]. 
These national data could be supplemented by information from surveys [68] of new 
cannabis treatment entrants that ask them about: their reasons for seeking treatment; the type 
and amounts of cannabis that they use; their usual routes of administration; and where they 
have obtained their cannabis (to assess the extent to which the black market is still being used 
by the heaviest cannabis users). 
 
Effects on Other Health Outcomes 
 
It will be important to assess the contributions that alcohol- and cannabis-impaired driving 
make to motor vehicle accidents. This research will need to assess to what extent cannabis is 
a substitute for alcohol in young men, the population group at greatest risk of alcohol and 
cannabis abuse and MVAs. Such evaluations should also examine possible effects of cannabis 
legalization on rates of other types of alcohol related harm such as suicides and assaults.  
 
It will also be important to monitor any effects that cannabis legalization may have on 
tobacco smoking among adolescents and young adults. In past decades when tobacco 
smoking rates among youth in the USA were higher, a “gateway” hypothesis was proposed to 
explain a common pathway from early tobacco and alcohol use to an increased chance of 
later cannabis use. With the decline in youth tobacco use, evidence has emerged of a possible 
“reverse gateway effect” in which the initiation of cannabis smoking increases the later 
uptake of tobacco smoking [69]. 
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It will also be important to assess the social distribution of any adverse effects of cannabis 
legalization. A common argument in favour of cannabis legalization is that it will eliminate 
the discriminatory imposition of criminal penalties for cannabis use on minority users [23]. It 
will therefore be important to assess the effects of legalization on these minority groups, e.g. 
are these groups over-represented among heavy cannabis users who seek treatment? Have 
racial inequalities in drug arrests been reduced by cannabis legalization [70]?  
 
The Need for Better Evaluation Designs  
 
Ideally evaluations of the public health impact of cannabis legalization need to use stronger 
designs than the ecological studies assessing differences between states in time series data on 
health outcomes such as car crash fatalities, suicides or opioid overdose deaths. The results of 
these types of studies are open to many competing explanations. Assessing the plausibility of 
these explanations requires more detailed data on individuals‟ use of cannabis and other drugs 
and individual level data on the relationships between cannabis and other drug use and these 
kinds of harm within states. Federal agencies may need to increase the state sample sizes in 
national household and school surveys to enable valid and statistically powerful comparisons 
between cannabis use and cannabis-related outcomes in states that have adopted different 
cannabis policies. 
 
In principle, the emerging variability among US state cannabis laws, and the variations in the 
timing of these changes, will allow researchers to assess whether any effects on cannabis use 
and cannabis-related harm found in the early adopter states are replicated in states that are 
later adopters. The challenge for researchers will be to realize this opportunity. When 
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politicians introduce new legislation they generally do not give a high priority to doing so in a 
way that will enable researchers to conduct valid controlled evaluations of natural policy 
experiments, despite Donald Campbell‟s argument over 50 years ago that we should treat all 
reforms as experiments [71]. Delays in obtaining research funding may make it difficult to 
obtain baseline data on patterns of cannabis use. Funding agencies may need to find flexible 
ways of contracting researchers to evaluate the effects of these policy changes.  
Research Benefits of Cannabis Legalization  
 
In principle, cannabis legalization will also make it possible to monitor how much cannabis is 
sold because sales data will be a by-product of regulation. Measures of the THC and CBD 
content of cannabis products could also be required by the regulatory authorities as a 
condition of licensing. These data would allow us to estimate the amount of THC consumed 
by heavy users and per capita THC consumption.  
 
Waste water monitoring of cannabis metabolites could potentially be a cheaper way to 
estimate the community‟s cannabis consumption [59], if challenges in the quantification of 
THC and its metabolites in waste water can be addressed [72]. This would potentially enable 
waste water analyses to assess the size of the black market from the gap between legal sales 
of THC and the total amount of THC consumed in the population.  
 
Cannabis legalization will also make it easier to research the health effects of recreational 
cannabis use. It will be easier, for example, to study representative samples of adult users and 
address questions that have been difficult to answer under prohibition, namely: what doses of 
THC and CBD do regular cannabis users typically obtain? To what extent do they titrate their 
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doses of THC when using more potent cannabis products? Does the ability to titrate dose vary 
with the route of administration?  
 
If the conflict between US Federal and State cannabis laws can be resolved, it will also be 
easier to study the therapeutic benefits of cannabis and cannabinoids. Legalization will 
reduce the distorting effects of cannabis prohibition and reduce the strategic use of medical 
cannabis laws as a stepping stone to legalization of recreational use [73].  
 
Conclusions 
 
The legalization of recreational cannabis use in the USA is a large scale public health 
experiment whose outcomes may be unclear for a decade. The legalization of medical 
cannabis use has so far not produced marked increases in cannabis use among youth but it 
does seem to have increased cannabis use and cannabis-related problems among adult users. 
The modest impact of medical cannabis laws to date cannot be used to predict that the same 
will be true of cannabis outcomes in states that legalize retail sales to adults. The latter is a 
much more radical policy change. Given our experience with alcohol, legalization is likely to 
substantially reduce the price of cannabis, increase heavy use, and increase some types of 
cannabis-related harm, among existing users. In the longer term it may also increase the 
number of new users. 
 
The creation of legal cannabis markets for recreational use in the USA is at an early stage of 
implementation so it is too soon to assess whether it has increased cannabis use and cannabis-
related harm. Future evaluations will need to look for the following types of evidence: more 
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favourable attitudes towards cannabis use among young people; increased frequency of use 
among at risk youth (e.g. those who seek help for cannabis use and mental health problems 
and those in the criminal justice system); increased use and cannabis-related problems (car 
crashes, ED attendances for cannabis-related problems; increased treatment seeking for 
cannabis use problems; and treatment for mental disorders) and cannabis use among adult 
cannabis users. An evaluation of this policy change should also assess how increases in 
cannabis use affect alcohol and tobacco use and other drug-related harm among youth and 
young adults. These results should ideally inform the design of any policy changes that are 
intended to reduce cannabis-related harm after legalization. 
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Table 1: Cannabis legalization provisions in four US states that have legalized cannabis 
 Alaska Colorado Oregon  Washington  
Passed  2014 2012 2014 2012 
Legal sales  2016 2014 2016  2014  
Legal age  21 years 21 years 21 years 21 years 
Legal Quantity  28.5 g 28.5 g 28.5 g 28.5 g 
Regulator 
 
Alcohol and 
Marijuana 
Control Office 
Marijuana 
Enforcement 
Division, Dept 
of Revenue 
Oregon Liquor 
Control 
Commission 
State Liquor 
and Cannabis 
Board 
Tax regime $50 state 
excise per 
28.5 g 
15% state excise 
included in sale 
price 
Tax free until 
2016 from 
dispensaries. 
Then 25% on 
nonmedical sales  
Retailer pays 
excise of 37% 
Licensing Cultivators, 
retailers, 
manufacturers, 
testing 
facilities 
Cultivators, 
retailers, 
manufacturers, 
testing facilities 
Producers, 
processors, 
wholesalers, 
retailers 
Producer, 
Processor, and 
retailer 
Medical 
Marijuana 
Allowed from 
age 18; until 
legal sales 
medical users 
can cultivate 
but not sell  
Allowed from 
age 18; taxed at 
lower rate  
Allowed from 
age 18. 
Purchases at 
retail stores not 
subject to sales 
tax 
Allowed from 
age 18; 
personal 
cultivation 
allowed for 
medical users 
Personal 
cultivation 
Allowed & 
untaxed; six 
plants (up to 3 
mature plants)  
Allowed at age 
21 and untaxed 
(six plant total) 
Allowed; up to 
four plants 
Not allowed 
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Drug-affected 
driving  
Prohibited Prohibited Prohibited Prohibited 
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Box 1: Adverse effects of chronic recreational cannabis smoking identified in 
epidemiological studies (Source: Hall and Degenhardt, 2009 [74]) 
 
Most probable adverse effects  
 
 a cannabis dependence syndrome (in around 1 in 10 users);  
 chronic bronchitis and impaired respiratory function in regular smokers; 
 psychotic symptoms and disorders in heavy users, especially those with a history of 
psychotic symptoms or a family history of these disorders; 
 impaired educational attainment among adolescents who use regularly;  
 subtle cognitive impairment in those who use daily for a decade or more. 
 
Possible adverse effects  
 respiratory cancers;  
 behaviour disorders in children whose mothers used cannabis while pregnant; 
 depressive disorders, mania, and suicide;  
 increased likelihood of using other illicit drugs in adolescents. 
  
 
 
 
